Company intelligence / Profile preview
Teclison
Princeton, New Jersey, United Statesteclison.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Teclison is conducting Phase 2 clinical trials for TATE plus anti-PD-1 in the USA and Taiwan. Several advanced cancer patients have achieved long-term survival in these trials. Some advanced cancer patients showed dramatic response after TATE plus anti-PD-1 treatment even after failing immunotherapy before enrollment, demonstrating synergy with immunotherapy. The company plans to report robust response for advanced HCC patients who were refractory to immunotherapy at an upcoming ASCO annual meeting.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Merck & Co. (Clinical Trial Collaboration and Supply Agreement)
Beyond the preview
Go deeper on Teclison.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Teclison.